➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Baxter
Johnson and Johnson
McKinsey
AstraZeneca

Last Updated: February 26, 2021

DrugPatentWatch Database Preview

XOLAIR Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for XOLAIR

Identify potential brand extensions & biosimilar entrants

SponsorPhase
NovartisPhase 1
Beth Israel Deaconess Medical CenterPhase 1
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.LtdPhase 1

See all XOLAIR clinical trials

Recent Litigation for XOLAIR

Identify key patents and potential future biosimilar entrants

PTAB Litigation
PetitionerDate
GEMoaB Monoclonals GmbH2019-12-20
2017-12-20

See all XOLAIR litigation

Pharmacology for XOLAIR
Mechanism of ActionIgE-directed Antibody Interactions
Physiological EffectDecreased IgE Activity

Patent Text Search: US Patents for XOLAIR

These patents were identified by searching patent claims

Supplementary Protection Certificates for XOLAIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
PA2016022 Lithuania   Start Trial PRODUCT NAME: RITUKSIMABAS; REGISTRATION NO/DATE: EU/1/98/067/001-002 20140321
132016000025345 Italy   Start Trial PRODUCT NAME: TRASTUZUMAB PER USO SOTTOCUTANEO(HERCEPTIN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/145/002, 20130828
122015000061 Germany   Start Trial PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
122016000049 Germany   Start Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
PA2015031 Lithuania   Start Trial PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
132016000070123 Italy   Start Trial PRODUCT NAME: RITUXIMAB IN ASSOCIAZIONE CON IALURONIDASI RICOMBINANTE UMANA - SOLUZIONE PER INIEZIONE SOTTOCUTANEA(MABTHERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/98/067/001-003, 20140326
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Moodys
McKesson
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.